Pune, Jan. 09, 2023 (GLOBE NEWSWIRE) — According to a new market research report titled, “Neurological Biomarkers Market by Type (Genomic, Metabolomic, Proteomic, Imaging), by Application (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis), and by End-user (Hospital & Laboratories, Independent Diagnostic Centers, Research Organization) – Global Outlook & Forecast 2022-2030″ published by Growth Plus Reports, the Neurological Biomarkers Market is expected to grow at a CAGR of 11.9% from 2021 to reach US$ 17.88 billion by 2030.
Download PDF Brochure of Neurological Biomarkers Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at:
https://growthplusreports.com/inquiry/request-sample/neurological-biomarkers-market/8040
Market Drivers
The primary driver of the global neurological biomarkers market is the increase in the incidence rate of neurological disorders such as dementia, Alzheimer’s disease, Parkinson’s disease, brain trauma, and migraine. In addition, the rising demand for minimally invasive testing methods and early identification of neurological disorders contributes to the global market expansion. The need for neurological biomarkers has increased due to their ability to speed up drug development. Similarly, the use of biomarkers in confirming diagnoses, determining treatments, and tracking illness progression has fueled the global market expansion. Additionally, the demand for neurological biomarkers is rising due to new developments, such as clusters of biomarkers or biomarker signatures. It is also projected that large corporations’ ongoing investments in R&D will accelerate the expansion of the worldwide neurological markers market.
The global neurological biomarkers market has been analyzed from four perspectives – type, application, end-user, and region.
Excerpts from ‘By Type Segmentation’
Based on type, the global neurological biomarkers market is classified into:
Genomic
Metabolomic
Proteomic
Imaging
The proteomic segment will hold the largest market share of the global neurological biomarkers market in 2021. For biomarker development, the proteomic analysis provides detailed protein profiling of tissue, plasma, serum, and cerebral spinal fluid (CSF). It thus plays an essential part in segment growth. Additionally, the demand for proteomics has increased owing to quantitative proteomics tools that can quickly and accurately measure hundreds of proteins from small sample sizes. Furthermore, proteomics enables the development of biomarkers using established mass spectrometry-based platforms and more recent platforms such as multiplexed immunoassays and aptamer methods by identifying disease-related protein changes, thereby fueling segment growth.
Excerpts from ‘By Application Segmentation’
Based on application, the global neurological biomarkers market is segmented into:
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Alzheimer’s disease dominates the global neurological biomarkers market, with the largest market share in 2021. The large percentage of the Alzheimer’s disease segment can be attributed largely to an increase in the overall prevalence. Alzheimer’s is the most common type of neurodegenerative disease. According to the WHO, around 55 million people live with dementia worldwide in which Alzheimer’s disease accounts for approximately 60% to 70% of all cases. Additionally, government and non-government organizations are funding Alzheimer’s-related research and development, which is anticipated to fuel the segment expansion.
Excerpts from ‘By Region Segmentation’
Based on region, the global neurological biomarkers market has been segmented into:
North America
Europe
Asia Pacific
The Rest Of The World
North America dominated the global neurological biomarkers market in 2021, followed by Europe. Asia Pacific market is anticipated to grow at the fastest CAGR during the forecast period. The region’s large share is attributed to the increased incidence rate of neurological disorders. According to the Centers for Disease Control and Prevention (CDC), around 6.5 million people are living with Alzheimer’s in U.S. It is one of the top 10 causes of death in U.S. Additionally, the increase in R&D funding for neurological biomarkers in the region is fueling the region’s expansion. Major market players are present in the region, and the government’s increased efforts to raise public awareness of neurological disorders are also anticipated to support regional growth.
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global neurological biomarkers market are:
Abbott Laboratories
Quanterix Corporation
Thermo Fisher Scientific Inc.
Qiagen
Bio-Rad Laboratories Inc.
Merck KGaA
Banyan Biomarkers Inc.
Johnson & Johnson
ACOBIOM
Myriad Genetics Inc.
DiaGenic ASA
Olink Biosciences
Browse Detailed Summary of Research Report with TOC:
https://growthplusreports.com/report/neurological-biomarkers-market/8040
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2020
Base Year – 2021
Forecasted Years – 2022 to 2030
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2021)
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY TYPE
Genomic
Metabolomic
Proteomic
Imaging
Others
GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY APPLICATION
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Scope of the Report:
Report Attribute
Details
Market size value in 2021
US$ 6.5 billion
Revenue forecast in 2030
US$ 17.88 billion
Growth Rate
CAGR of 11.9% from 2022 to 2030
Base year for estimation
2021
Forecast period
2022-2030
Segments covered
type, application, end-user, and region.
Regional scope
North America, Europe, Asia Pacific, and the Rest of the World (ROW)
VALUE PROPOSITIONS RELATED TO THE REPORT:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Winning imperatives
Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
Distributor Landscape Assessment
Pipeline Assessment
Pricing Intelligence
Customer Base Assessment
Investment & Initiatives Analysis
‘Business Profile’ of Key Players
Directly Purchase Premium Copy of Neurological Biomarkers Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=WHuocJKe4tQgoVEJ1wkPm2mDhYiHgdXWIqpAgXgp&report_id=8040&license=Single
About Us
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a U.S.-based joint venture named Magdalena Biosciences, Inc. to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults. Initial funding of US$1,000,000 will be invested by Boulder, Colorado-based One Small Planet, founded by Will Peterffy. This fund
You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu. The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY), received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) last week. Biogen has been in this position before.
Pfizer's immunology drug candidate could be approved to treat a type of inflammatory bowel disease.
While Biogen's new CEO says he isn't planning any "radical left turns," he does see some ways the company could tap into new markets, including immunology and rare diseases.
Manuel Chimal put off being vaccinated, and nearly died. Now he's encouraging everyone to get their shot.
CVS Health Corp. is investing in a young chain of health clinics, and may be looking to acquire another.
Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
CureVac shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline . CureVac said the COVID-19 shot was well tolerated, and that neutralizing antibodies were beginning at the lowest tested dose for younger adults. The seasonal flu shot was also well tolerated with an increase in antib
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
Programs Dell Children's hospital pledged in first year now being developed, more being envisioned as it sets out to be a destination medical center.
With rates rising, biotech has faded. Investors have favored the pharma stalwarts. Bank of America’s drug analyst Geoff Meacham runs through the one’s to watch and a few to avoid. Plus: Could it be another banner year for Devon Energy?
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
The price set by the companies is higher than some analyst estimates of about $20,000. "As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide," BMO analyst Evan Seigerman said in a research note. However, the price tag is lower than that of Eisai and Biogen's first Alzheimer's disease drug, Aduhelm, which was initially priced at $56,000 annually before the drugmakers halved the price amid controversy over its approval.
Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
(Bloomberg) — In the past three years, biotech companies have enjoyed a raft of successes, including rapidly developing vaccines for Covid-19, discovering a drug that can slow the progress of Alzheimer’s disease and securing approvals for one-time gene therapies for hard-to-treat conditions.Most Read from BloombergUS Safety Agency to Consider Ban on Gas Stoves Amid Health FearsGoldman to Cut About 3,200 Jobs This Week After Cost ReviewCommodity Ship Heads for Inspection After Suez Canal MishapS
Belite Bio (NASDAQ: BLTE), TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding treatments for maladies with no approved treatments, a more effective way to do organ transplants, or a more precise way to treat disorders that lead to obesity. Belite Bio is a clinical-stage biopharmaceutical company that focuses on therapies to treat blindness, diabetes, and liver disease.
Chinese officials say they have "safe and effective" vaccines as Beijing rebuffs mRNA shots from the U.S. and the EU.
A newly approved drug for Alzheimer's disease is providing a sense of hope for some people fighting the disease. The Food and Drug Administration on Friday granted accelerated approval to lecanemab, which will be sold under the name Leqembi, after clinical trials showed the drug slows cognitive decline in patients with early Alzheimer's disease. The treatment is a monoclonal antibody infusion given to patients biweekly. Some questions and concerns remain about the drug's safety, and how most people will afford the treatment, but even still, FDA approval is enough reason for Dennis Myers to be optimistic. Time is of the essence for Myers, who has early Alzheimer's disease, to have more time with family and more time with the memories he holds dear.
Last year, the Nasdaq Composite experienced a downturn due to a combination of negative economic and political factors. At any rate, economic issues won't last forever, and the market will eventually continue its march forward. One growth stock that can help with that is none other than DexCom (NASDAQ: DXCM).
